PD-1 blockade provides clinical benefit in gastrointestinal cancers, yet the sites and immune cell populations initiating effective anti-tumor immunity through the treatment remain unclear. The authors here show that anti-PD-1 antibodies activate PD-1⁺TCF1⁺ progenitor exhausted CD8⁺ T cells in lymph nodes that expand and infiltrate tumors to mediate immunity.
- Yohei Nose
- Yoshiaki Yasumizu
- Yuichiro Doki
